4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide

• ChemBase编号: 4379
• 分子式: C29H41F2N5O
• 平均质量: 513.6655464
• 单一同位素质量: 513.3279174
• SMILES: FC1(F)CCC(C(=O)N[C@@H](CCN2[C@H]3CC(n4c(nnc4C)C(C)C)C[C@@H]2CC3)c2ccccc2)CC1
• Canonical SMILES: O=C(C1CCC(CC1)(F)F)N[C@H](c1ccccc1)CCN1[C@@H]2CC[C@H]1CC(C2)n1c(C)nnc1C(C)C
• InChI: InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
• InChIKey: GSNHKUDZZFZSJB-HLMSNRGBSA-N

名称和登记号

名称

• IUPAC标准名: 4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
• IUPAC传统名: maraviroc
• 商标名: Selzentry; Celsentri
• 别名: maraviroc; Maraviroc

登记号

• CAS号: 376348-65-1
• PubChem SID: 46508040; 160967811
• PubChem CID: 3002977

理论计算性质

JChem

• Acid pKa: 14.495693
• 质子受体: 4
• 质子供体: 1
• LogD (pH = 5.5): 0.27627262
• LogD (pH = 7.4): 1.6587688
• Log P: 3.6262107
• 摩尔折射率: 142.8808 cm^3
• 极化性: 54.23912 Å^3
• 极化表面积: 63.05 Å^2
• 可自由旋转的化学键: 8
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 4.3
• LOG S: -4.68
• 溶解度: 1.06e-02 g/l

详细说明

DrugBank - DB04835

• Drug Groups: approved; investigational
• Description: Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
• Indication: For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
• Pharmacology: Maraviroc is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5.
• Affected Organisms: Human Immunodeficiency Virus
• Biotransformation: In vitro studies indicate that CYP3A is the major enzyme responsible for maraviroc metabolism.
• Absorption: The absolute oral bioavailability of a 100 mg dose is 23% and is predicted to be 33% at 300 mg. Coadministration of a 300mg tablet with a high fat breakfast reduced maraviroc Cmax and AUC by 33% in healthy volunteers.
• Half Life: 14-18 hours
• Protein Binding: Approximately 76% bound to human plasma proteins, with moderate affinity for albumin and alpha-1 acid glycoprotein.
• Distribution: * 194 L
• External Links: Wikipedia; RxList; Drugs.com